You are leaving Medscape Education
Cancel Continue
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Business of Medicine
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Interprofessional
Shared Decision Making
Nurses
Pharmacists
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Sunday, October 1, 2023
      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

      Clinical Advances in PNH

      Read Overview

      Supported by an independent educational grant from Apellis Pharmaceuticals.                                                                                                                      

      Overview

      Clinical Advances in PNH

      Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening disease in which uncontrolled complement activation leads to nonimmune hemolytic anemia. PNH is frequently accompanied by bone marrow failure and is associated with an increased risk of thrombosis and potentially mortality, particularly if the PNH is not appropriately treated. The treatment of PNH has improved in recent years with the introduction of complement-directed therapies. Newer therapies targeting various components of the complement pathway are also in development. On this page, you'll find a collection of accredited educational programs that are dynamic and interactive, in which international expert faculty review clinician pearls on the diagnosis of PNH and discuss the latest data on and current and emerging treatment approaches.

      CME Activities

      Apply what you know about PNH

      Test your knowledge against your colleagues in an exciting series of 2-3 minute medical questions.

      Resources

      Downloadable Slide Kit
      Clinical Reference
      Related Links

      Steering Committee

      Peter Hillmen, MBChB, PhD
      Peter Hillmen, MBChB, PhD

      Steering Committee Chair

      Professor of Experimental Haematology, St James's University Hospital, Leeds, United Kingdom

      Catherine M. Broome, MD
      Catherine M. Broome, MD

      Associate Professor, Department of Medicine, Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, DC, United States

      Carlos de Castro, MD
      Carlos de Castro, MD

      Professor of Medicine, Duke University School of Medicine, Member, Duke Cancer Institute, Durham, North Carolina, United States

      Morag Griffin, MBChB, FRCPath
      Morag Griffin, MBChB, FRCPath

      Consultant Haematologist, St James's University Hospital, Leeds, United Kingdom

      Ilene Ceil Weitz, MD
      Ilene Ceil Weitz, MD

      Professor and Graduate Program Director, Gwynedd Mercy University, Gwynedd Valley, Pennsylvania, United States

      Disclosures

      Steering Committee

      Peter Hillmen, MBChB, PhD

      Steering Committee Chair

      Has disclosed the following relevant financial relationships:

      Served as an advisor or consultant for: AbbVie; Alexion Pharmaceuticals; Apellis Pharmaceuticals; AstraZeneca; Janssen (J&J)

      Served as a speaker or a member of a speakers bureau for: AbbVie; AstraZeneca; Janssen (J&J)

      Other: Employer (University of Leeds) has received research grants from AbbVie; Apellis Pharmaceuticals; Janssen; Pharmacyclics

      Catherine M. Broome, MD

      Steering Committee Member

      Has disclosed the following relevant financial relationships:

      Served as an advisor or consultant for: Alexion Pharmaceuticals; Apellis Pharmaceuticals; Argenx; Sanofi

      Served as a speaker or a member of a speakers bureau for: Alexion; Apellis; Argenx; Sanofi

      Carlos de Castro, MD

      Steering Committee Member

      Has disclosed the following relevant financial relationships:

      Served as an advisor or consultant for: Alexion Pharmaceuticals; Apellis Pharmaceuticals; Biocryst Pharmaceuticals

      Received grants for clinical research from: Alexion Pharmaceuticals; Apellis Pharmaceuticals; Biocryst Pharmaceuticals

      Morag Griffin, MBChB, FRCPath

      Steering Committee Member

      Has disclosed the following relevant financial relationships:

      Served as an advisor or consultant for: Alexion Pharmaceutical; Biocryst Pharmaceuticals

      Served as a speaker or a member of a speakers bureau for: Alexion Pharmaceuticals

      Ilene Ceil Weitz, MD

      Steering Committee Member

      Has disclosed the following relevant financial relationships:

      Served as an advisor or consultant for: Alexion Pharmaceuticals; Apellis Pharmaceuticals

      Served as a speaker or a member of a speakers bureau for: Alexion Pharmaceuticals; Apellis Pharmaceuticals

      Discussion

      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.